Beta Cat Pharmaceuticals' Unattributed - II Round

Beta Cat Pharmaceuticals raised a round of funding on July 08, 2014.

Beta Cat Pharmaceuticals is developing compounds which modulate beta catenin and are in the translational phase. These compounds target beta catenin, the end result of seminal mutations in the APC/WNT…

Articles about Beta Cat Pharmaceuticals' Unattributed - II Round: